Astellas Pharma

Company snapshot

Astellas is a global life sciences company committed to turning innovative science into VALUE for patients. We provide transformative therapies in disease areas that include oncology, ophthalmology, urology, immunology and women's health. Through our research and development programs, we are pioneering new healthcare solutions for diseases with high unmet medical need. Visit our Global Astellas Li

• 1 active pipeline program(s) linked via ClinicalTrials.gov.
• 10 US patent(s) indexed to this assignee profile.
• 1 trial update(s) in the last 12 months.

Public regulatory, clinical, patent, and corporate records for Astellas Pharma. Not investment advice.

Recent activity

Latest pipeline, patent, and corporate events for Astellas Pharma.

1. Jun 8, 2026 Clinical update

   Solifenacin succinate — Phase 3

2. Aug 1, 2025 Patent grant

   Combination therapy of bispecific binding agents that bind to CLDN18.2 and CD3 with immune checkpoint inhibitors

3. Mar 12, 2024 Patent grant

   CLDN18.2 및 CD3에 결합하는 이중특이 결합제

4. Dec 2, 2015 Patent grant

   Composition of tiacumicin compounds

5. Jul 6, 2005 Patent grant

   VERBINDUNGEN AUF GLUKOSEBASIS MIT AFFINITÜT FÜR P-SELEKTIN

View all clinical trial activity →

• What is Astellas Pharma?

  Astellas Pharma Europe is a pharma organization headquartered in EU. Primary therapeutic focus areas include Neurogenic Detrusor Overactivity. NovaPharmaNews links 1 clinical program(s), 0 drug profile(s), and 0 patent record(s) to this entity from public FDA, EMA, ClinicalTrials

• Is Astellas Pharma publicly traded?

  Astellas Pharma appears in our database through regulatory marketing authorisation or clinical trial sponsor records; a US listed ticker is not shown for this entity.

• What drugs does Astellas Pharma develop or market?

  We link 2 drug profile(s) where Astellas Pharma is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/astellas-pharma-europe-b-v-eu#company-drugs.

• What are the latest developments for Astellas Pharma?

  In the last 12 months our linked public records show 1 trial program update(s) and 0 US patent grant(s) tied to this profile.

• What therapeutic areas does Astellas Pharma focus on?

  Astellas Pharma focuses on Neurogenic Detrusor Overactivity based on our analysis of their pipeline programs and drug development activities.